Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

735 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.
Fenwarth L, Fournier E, Cheok M, Boyer T, Gonzales F, Castaigne S, Boissel N, Lambert J, Dombret H, Preudhomme C, Duployez N. Fenwarth L, et al. Among authors: fournier e. Int J Mol Sci. 2020 Aug 6;21(16):5626. doi: 10.3390/ijms21165626. Int J Mol Sci. 2020. PMID: 32781546 Free PMC article. Review.
Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature.
Fournier E, Inchiappa L, Delattre C, Pignon JM, Danicourt F, Bemba M, Roche-Lestienne C, Daudignon A, Decool G, Roumier C, Dumezy F, Fournier L, Grardel N, Preudhomme C, Duployez N. Fournier E, et al. Among authors: fournier l. Leuk Lymphoma. 2019 Jul;60(7):1827-1830. doi: 10.1080/10428194.2018.1562185. Epub 2019 Jan 7. Leuk Lymphoma. 2019. PMID: 30616415 Review. No abstract available.
Familial myeloid malignancies with germline TET2 mutation.
Duployez N, Goursaud L, Fenwarth L, Bories C, Marceau-Renaut A, Boyer T, Fournier E, Nibourel O, Roche-Lestienne C, Huet G, Beauvais D, Berthon C, Cambier N, Quesnel B, Preudhomme C. Duployez N, et al. Among authors: fournier e. Leukemia. 2020 May;34(5):1450-1453. doi: 10.1038/s41375-019-0675-6. Epub 2019 Dec 11. Leukemia. 2020. PMID: 31827242 No abstract available.
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.
Fournier E, Duployez N, Ducourneau B, Raffoux E, Turlure P, Caillot D, Thomas X, Marceau-Renaut A, Chantepie S, Malfuson JV, Lemasle E, Cheok M, Celli-Lebras K, Guerin E, Terré C, Lambert J, Pautas C, Dombret H, Castaigne S, Preudhomme C, Boissel N. Fournier E, et al. Blood. 2020 Feb 20;135(8):542-546. doi: 10.1182/blood.2019003471. Blood. 2020. PMID: 31880804 Free article. Clinical Trial.
When leukocytes bite off more than they can chew.
Dechaux-Blanc D, Zerimech F, Guemann AS, Duployez N, Fournier E. Dechaux-Blanc D, et al. Among authors: fournier e. Am J Hematol. 2020 Apr;95(4):447-448. doi: 10.1002/ajh.25720. Epub 2020 Jan 23. Am J Hematol. 2020. PMID: 31903643 Free article. No abstract available.
B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL.
Fournier B, Balducci E, Duployez N, Clappier E, Cuccuini W, Arfeuille C, Caye-Eude A, Delabesse E, Bottollier-Lemallaz Colomb E, Nebral K, Chrétien ML, Derrieux C, Cabannes-Hamy A, Dumezy F, Etancelin P, Fenneteau O, Frayfer J, Gourmel A, Loosveld M, Michel G, Nadal N, Penther D, Tigaud I, Fournier E, Reismüller B, Attarbaschi A, Lafage-Pochitaloff M, Baruchel A. Fournier B, et al. Among authors: fournier e. Front Oncol. 2019 Dec 10;9:1374. doi: 10.3389/fonc.2019.01374. eCollection 2019. Front Oncol. 2019. PMID: 31921638 Free PMC article.
Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignancies.
Fournier E, Debord C, Soenen V, Trillot N, Gonzales F, Tintiller V, Terriou L, Derrieux C, Abou Chahla W, Paris C, Berthon C, Boyer T, Lambilliotte A, Boisseau P, Wuillème S, Fouassier M, Susen S, Preudhomme C, Duployez N. Fournier E, et al. Br J Haematol. 2020 May;189(4):e119-e122. doi: 10.1111/bjh.16543. Epub 2020 Feb 27. Br J Haematol. 2020. PMID: 32103500 Free article. No abstract available.
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.
Gardin C, Pautas C, Fournier E, Itzykson R, Lemasle E, Bourhis JH, Adès L, Marolleau JP, Malfuson JV, Gastaud L, Raffoux E, Lambert J, Braun T, Thomas X, Chantepie S, Cluzeau T, de Botton S, Berthon C, Boissel N, Duployez N, Terré C, Peffault de Latour R, Michallet M, Celli-Lebras K, Preudhomme C, Dombret H. Gardin C, et al. Among authors: fournier e. Blood Adv. 2020 May 12;4(9):1942-1949. doi: 10.1182/bloodadvances.2019001349. Blood Adv. 2020. PMID: 32380535 Free PMC article.
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use.
Lesieur A, Thomas X, Nibourel O, Boissel N, Fenwarth L, De Botton S, Fournier E, Celli-Lebras K, Raffoux E, Recher C, Lambert J, Berthon C, Pigneux A, Itzykson R, Turlure P, Pautas C, Vargaftig J, Preudhomme C, Dombret H, Duployez N. Lesieur A, et al. Among authors: fournier e. Haematologica. 2021 Jun 1;106(6):1767-1769. doi: 10.3324/haematol.2020.260133. Haematologica. 2021. PMID: 33299234 Free PMC article.
735 results